Section
The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted th
This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in bio
This review explores the potential of targeting HBx-induced HSPB1 to suppress HBV cccDNA and enhance hepatic immune responses, highlighting a promising peptide-based therapeutic approach.
This review analyzes current evidence supporting the use of GLP-1 and GIP/GLP-1 receptor agonists in IIH, highlighting benefits in reducing papilledema, visual disturbances, and headaches.
This study highlights the association between illicit anabolic steroid use and adverse cardiovascular outcomes in both sexes, emphasizing the need for preventive strategies in recreational sports.
This article reviews recent evidence comparing weight loss outcomes and healthcare costs of bariatric surgery and GLP-1 receptor agonists, highlighting implications for clinical decision-making in treating class II and III obesity.
This systematic review and meta-analysis evaluate cancer and graft outcomes in transplant recipients treated with immune checkpoint inhibitors, revealing differences by cancer type and potential strategies to reduce rejection risk.
This article reviews a pivotal phase 3 trial demonstrating telitacicept’s efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.
Obesity management in cardiac rehabilitation (CR) is underutilized despite its cardiovascular benefits. This review explores the evidence, complexities, patient perspectives, and healthcare provider attitudes, emphasizing tailored strategie
This review discusses a landmark study demonstrating how wearable devices and online coaching improve exercise capacity in coronary artery disease patients, highlighting advancements in remote cardiac rehabilitation.
NRTIs, traditionally used in HIV and HBV treatment, demonstrate promising anti-inflammatory effects that may reduce the incidence of age-related diseases by inhibiting inflammaging processes associated with endogenous retroelements.
The MePFAC trial demonstrates that methylphenidate is safe but does not significantly reduce fatigue compared to placebo in advanced cancer patients receiving palliative care, challenging previous assumptions about its efficacy.
A phase 2b trial reveals that single doses of MM120 produce dose-dependent reductions in anxiety symptoms in adults with moderate to severe generalized anxiety disorder, paving the way for phase 3 studies.
This study links Alzheimer’s disease-related blood biomarkers with accelerated muscle strength loss over 12 years, highlighting the interplay between neurodegeneration and physical decline in aging populations.
This prospective Spanish cohort study reveals that moderate-to-vigorous physical activity enhances intrinsic capacity in older adults, while sedentary behavior impairs it, underscoring the role of active lifestyles in promoting healthy agei
A 30-year birth cohort study reveals that life-course factors, especially modifiable markers like BMI, blood glucose, and blood pressure, significantly influence the buildup of chronic diseases across eight organ systems, yet much remains u
The GBD 2023 Study integrates data from 204 countries to reveal shifting global mortality patterns, emphasizing the impact of COVID-19, declining vaccine-preventable deaths, and rising non-communicable diseases, highlighting critical areas
The Hospital Frailty Risk Score (HFRS) predicts length of stay, mortality, and costs across all adult age groups in England, with stronger effects in older adults, supporting broader clinical use beyond the elderly.
This cohort study from the Young Finns Study elucidates factors influencing blood-based biomarkers for neurodegenerative diseases, highlighting age, APOE ε4 genotype, kidney function, metabolic parameters, and notable intergenerational asso
The G-oncoCOACH trial demonstrates that comprehensive geriatric assessment combined with geriatric team implementation and extensive patient coaching significantly improves quality of life in older patients with solid tumors undergoing syst
